ArticleFrontiers in oncology2026
Case Report: Primary epithelioid sarcoma of orbit: first case in Asia and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epithelioid sarcoma is an exceedingly rare malignant soft tissue neoplasm with unclear histogenesis and distinctive epithelioid morphology. Primary epithelioid sarcoma of orbit represents an extremely rare clinical entity, with only isolated case reports documented globally. Notably, no formal, peer-reviewed case report of primary epithelioid sarcoma of orbit has been published in Asia to date. Case presentation: A 25-year-old male patient presented with slowly progressive, painless proptosis of the left eye. Orbital MRI revealed an irregular mass in the superomedial extraconal space of the left orbit, with an initial radiological impression of vascular tumor or inflammatory lesion. Histologically, the tumor displayed characteristic multinodular growth, composed of a mixture of epithelioid and spindle cells with necrotizing granuloma-like changes. Skeletal muscle invasion and vascular tumor emboli were observed. Immunohistochemically, tumor cells co-expressed epithelial markers (broad-spectrum CK, EMA), mesenchymal marker (Vimentin) and CD34, with loss of nuclear INI1 (SMARCB1) expression. Whole-body PET-CT performed postoperatively excluded distant metastasis, and a diagnosis of classic primary epithelioid sarcoma of the left orbit was confirmed. The patient underwent extended tumor resection combined with local intensity-modulated radiotherapy. No local recurrence or distant metastasis was detected at 7 months postoperatively. Conclusions: Primary epithelioid sarcoma of the orbit is diagnostically challenging, and pathological examination remains the gold standard for diagnosis. The combination of characteristic histological features and a distinct immunophenotype (loss of INI1) is critical for definitive diagnosis and differential diagnosis. We report the first case of primary epithelioid sarcoma of orbit in Asia, which enriches the clinicopathological data of this rare tumor in the Asian population and provides a key reference for its clinical management and pathological diagnosis. However, as a single-case study, larger series are needed to confirm generalizability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.